Medications

Teva stops selling migraine patch after reports of burns

Teva Pharmaceutical said Monday that it will stop selling its migraine patch treatment Zecuity after users reported burns and scars where it was applied. The company advised that anyone who has its patch should not use it.

Medications

FDA approves cinqair for severe asthma

(HealthDay)—Cinqair (reslizumab) has been approved by the U.S. Food and Drug Administration to treat severe asthma among adults 18 and older.

Medications

France to call for lower drug prices at G7

France will announce a campaign to lower the price of new medicines, hoping world powers at the upcoming G7 meeting will put pressure on the pharmaceutical industry, its health minister said Tuesday.

Medical research

Screening enormous databases to find a cure for cancer

Developing new drugs is becoming increasingly difficult: research and lab experiments are time consuming and expensive. By making use of data first – screening large databases in order to discover patterns - we can make ...

Neuroscience

Potential new drug therapy for peripheral nerve damage announced

The Mount Desert Island (MDI) Biological Laboratory has announced that assistant professor Sandra Rieger, Ph.D., has identified two drugs that could potentially be used to reverse peripheral nerve damage, or peripheral neuropathy, ...

Medications

Experts: High drug price trend has 'infected' generics

An article published online today in Blood, the Journal of the American Society of Hematology (ASH), suggests that pharmaceutical companies use several strategies to keep affordable generic drugs from the market, illustrating ...

Other

Valeant in new distribution deal with Walgreens

Valeant Pharmaceuticals regained some credibility with upset investors thanks to its announcement Tuesday of a new distribution deal with Walgreens and plans to line up more pharmacies to sell its products after a scandal ...

page 37 from 40